Reviewer’s report

Title: ENOXAPARIN ATTENUATES DOXORUBICIN INDUCED CARDIOTOXICITY IN RATS VIA INTERFERING WITH OXIDATIVE STRESS, INFLAMMATION AND APOPTOSIS

Version: 0 Date: 01 Aug 2017

Reviewer: Wissam Faour

Reviewer’s report:

Dear Editor

1) The authors proposed that ENX has cardioprotective effect and opposes to Doxorubicin cardiac damaging effects. The hypothesis is interesting, the experimental design is incomplete and lack additional components.

2) The authors are required to elaborate on the role of doxorubicin on heart function, and also if possible to measure the rodent blood pressure. Also, renal function is tightly associated with cardiac function, it is advisable to evaluate the effect of the drugs on kidney function activities (e.g., measuring GFR).

3) In table 1, heart weight in the control group is higher than of the DOX-treated animals. While hypertrophy due to DOX will lead to increase in heart weight rather than weight loss, how can the author explain this discrepancy? Same to heart weight/body weight. Also, the ENX group didn't cause an improvement in the heart/body weight, please provide an explanation.

4) The author should also provide results for rat group treated with ENX alone

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

 Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal